Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimation of skin sodium content via <sup>23</sup>Na magnetic resonance imaging at 3 T using a single-loop surface transmit/receive coil.

Magma (New York, N.Y.)·2026
Same author

Central Systolic Blood Pressure and Left Ventricular Mass: Findings From the International 24-Hour Aortic Blood Pressure Consortium.

Journal of the American Heart Association·2026
Same author

Echocardiographic assessment in arterial hypertension: a contemporary narrative review.

Echo research and practice·2026
Same author

Economic and Resource Use-Related Guidance in US Medical Societies' Clinical Practice Guidelines.

JAMA network open·2026
Same author

Reshaping the progranulin/sortilin interaction for targeted degradation of extracellular proteins.

Cell chemical biology·2026
Same author

P2X7R-mediated IL-1β release by human brain tissue: the impact of CNS-penetrant potential therapeutics.

Brain : a journal of neurology·2026

Related Experiment Video

Updated: Oct 9, 2025

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies
04:47

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies

Published on: February 23, 2018

7.9K

Fc-engineered antibodies with immune effector functions completely abolished.

Ian Wilkinson1,2, Stephen Anderson1, Jeremy Fry3

  • 1Absolute Antibody Ltd, Wilton, United Kingdom.

Plos One
|December 21, 2021
PubMed
Summary

Novel Fc variants eliminate binding to Fc gamma receptors (FcγR) and C1q, preventing inflammatory responses. These engineered antibodies maintain FcRn binding and stability, enhancing therapeutic protein safety and efficacy.

More Related Videos

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

7.0K
Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

9.9K

Related Experiment Videos

Last Updated: Oct 9, 2025

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies
04:47

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies

Published on: February 23, 2018

7.9K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

7.0K
Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

9.9K

Area of Science:

  • Biotechnology
  • Immunology
  • Protein Engineering

Background:

  • Therapeutic antibodies and fusion proteins can trigger unwanted inflammatory responses due to binding of the immunoglobulin Fc region to Fc gamma receptors (FcγR).
  • Existing methods to eliminate FcγR binding are often incomplete, failing to address all Fcγ receptor subtypes.
  • Minimizing FcγR interactions is crucial for improving the safety profile of protein-based therapeutics.

Purpose of the Study:

  • To develop novel Fc variants with significantly reduced or eliminated binding to Fc gamma receptors (FcγR) and C1q.
  • To assess the impact of these variants on FcRn binding, manufacturability, stability, and immunogenicity.
  • To evaluate the functional activity and inflammatory potential of the engineered Fc variants in cell-based assays.

Main Methods:

  • Engineering of Fc variants through specific amino acid substitutions in the Fc region, including L234A, L235A, and G236R.
  • Assessment of FcγR and C1q binding using various assays.
  • Evaluation of FcRn binding, protein stability, and manufacturability.
  • Functional characterization through cell-based assays and measurement of inflammatory cytokine responses.

Main Results:

  • The novel Fc variants demonstrated no detectable binding to Fcγ receptors or C1q.
  • These variants were inactive in functional cell-based assays and did not induce inflammatory cytokine production.
  • Crucially, binding to FcRn, manufacturability, stability, and potential immunogenicity remained unaffected by the engineered substitutions.

Conclusions:

  • Engineered Fc variants with specific amino acid substitutions effectively eliminate FcγR and C1q binding.
  • These variants represent a promising strategy for reducing immunogenicity and improving the safety of therapeutic antibodies and Fc fusion proteins.
  • The unaffected FcRn binding and other critical properties suggest broad applicability in protein therapeutics.